David S Jones's most recent trade in Shore Bancshares Inc. was a trade of 3,306 Common Stock done at an average price of $11.2 . Disclosure was reported to the exchange on May 30, 2024.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Shore Bancshares Inc. | David S. Jones | Director | Grant, award, or other acquisition of securities at price $ 11.19 per share. | 30 May 2024 | 3,306 | 11,531 (0%) | 0% | 11.2 | 36,994 | Common Stock |
| EyePoint Pharmaceuticals Inc | David Scott Jones | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2024 | 5,000 | 48,572 (0%) | 0% | 0 | Common Stock | |
| EyePoint Pharmaceuticals Inc | Jones Scott David | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2024 | 5,000 | 5,000 | - | - | Restricted Stock Units | |
| EyePoint Pharmaceuticals Inc | Scott David Jones | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2024 | 4,967 | 43,572 (0%) | 0% | 0 | Common Stock | |
| EyePoint Pharmaceuticals Inc | Scott David Jones | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2024 | 4,967 | 0 | - | - | Restricted Stock Units | |
| EyePoint Pharmaceuticals Inc | David Scott Jones | SVP & Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 28.80 per share. | 09 Feb 2024 | 1,955 | 46,617 (0%) | 0% | 28.8 | 56,304 | Common Stock |
| EyePoint Pharmaceuticals Inc | David Jones Scott | SVP & Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 28.80 per share. | 09 Feb 2024 | 1,701 | 44,916 (0%) | 0% | 28.8 | 48,989 | Common Stock |
| Shore Bancshares Inc. | S. David Jones | Director | Purchase of securities on an exchange or from another person at price $ 11.01 per share. | 08 Feb 2024 | 8,043 | 35,235 (0%) | 0% | 11.0 | 88,553 | Common Stock |
| Shore Bancshares Inc. | S. David Jones | Director | Purchase of securities on an exchange or from another person at price $ 10.96 per share. | 08 Feb 2024 | 1,957 | 37,192 (0%) | 0% | 11.0 | 21,449 | Common Stock |
| EyePoint Pharmaceuticals Inc | Jones David Scott | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 11.47 per share. | 02 Feb 2024 | 209 | 38,171 (0%) | 0% | 11.5 | 2,397 | Common Stock |
| EyePoint Pharmaceuticals Inc | Jones Scott David | SVP & Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 28.49 per share. | 02 Feb 2024 | 209 | 37,962 (0%) | 0% | 28.5 | 5,954 | Common Stock |
| EyePoint Pharmaceuticals Inc | Scott David Jones | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Feb 2024 | 209 | 4,375 | - | - | Stock Option (Right to Buy) | |
| EyePoint Pharmaceuticals Inc | Jones David Scott | SVP & Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 25.45 per share. | 26 Jan 2024 | 16,413 | 47,566 (0%) | 0% | 25.4 | 417,653 | Common Stock |
| EyePoint Pharmaceuticals Inc | Jones David Scott | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.26 per share. | 26 Jan 2024 | 16,413 | 63,979 (0%) | 0% | 3.3 | 53,506 | Common Stock |
| EyePoint Pharmaceuticals Inc | Jones Scott David | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Jan 2024 | 16,413 | 68,742 | - | - | Stock Option (Right to Buy) | |
| EyePoint Pharmaceuticals Inc | Jones Scott David | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.90 per share. | 26 Jan 2024 | 9,604 | 47,566 (0%) | 0% | 12.9 | 123,892 | Common Stock |
| EyePoint Pharmaceuticals Inc | Scott David Jones | SVP & Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 25.27 per share. | 26 Jan 2024 | 9,604 | 37,962 (0%) | 0% | 25.3 | 242,717 | Common Stock |
| EyePoint Pharmaceuticals Inc | David Jones Scott | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Jan 2024 | 9,604 | 8,721 | - | - | Stock Option (Right to Buy) | |
| EyePoint Pharmaceuticals Inc | Jones David Scott | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.26 per share. | 24 Jan 2024 | 5,700 | 49,262 (0%) | 0% | 3.3 | 18,582 | Common Stock |
| EyePoint Pharmaceuticals Inc | David Scott Jones | SVP & Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 25.01 per share. | 24 Jan 2024 | 5,700 | 43,562 (0%) | 0% | 25.0 | 142,554 | Common Stock |
| EyePoint Pharmaceuticals Inc | David Jones Scott | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Jan 2024 | 5,700 | 85,455 | - | - | Stock Option (Right to Buy) | |
| EyePoint Pharmaceuticals Inc | Scott Jones David | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Jan 2024 | 5,600 | 18,625 | - | - | Stock Option (Right to Buy) | |
| EyePoint Pharmaceuticals Inc | David Scott Jones | SVP & Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 25.01 per share. | 24 Jan 2024 | 5,600 | 37,962 (0%) | 0% | 25.0 | 140,068 | Common Stock |
| EyePoint Pharmaceuticals Inc | David Jones Scott | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.90 per share. | 24 Jan 2024 | 5,600 | 43,562 (0%) | 0% | 12.9 | 72,240 | Common Stock |
| EyePoint Pharmaceuticals Inc | Jones David Scott | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Jan 2024 | 300 | 85,155 | - | - | Stock Option (Right to Buy) | |
| EyePoint Pharmaceuticals Inc | David Scott Jones | SVP & Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 25.00 per share. | 24 Jan 2024 | 300 | 38,262 (0%) | 0% | 25 | 7,500 | Common Stock |
| EyePoint Pharmaceuticals Inc | David Jones Scott | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Jan 2024 | 300 | 18,325 | - | - | Stock Option (Right to Buy) | |
| EyePoint Pharmaceuticals Inc | David Jones Scott | SVP & Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 25.00 per share. | 24 Jan 2024 | 300 | 37,962 (0%) | 0% | 25 | 7,500 | Common Stock |
| EyePoint Pharmaceuticals Inc | David Jones Scott | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.90 per share. | 24 Jan 2024 | 300 | 38,262 (0%) | 0% | 12.9 | 3,870 | Common Stock |
| EyePoint Pharmaceuticals Inc | Scott Jones David | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.26 per share. | 24 Jan 2024 | 300 | 38,562 (0%) | 0% | 3.3 | 978 | Common Stock |
| EyePoint Pharmaceuticals Inc | Jones Scott David | SVP & Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 22.69 per share. | 22 Jan 2024 | 28,750 | 37,962 (0%) | 0% | 22.7 | 652,254 | Common Stock |
| EyePoint Pharmaceuticals Inc | Scott Jones David | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Jan 2024 | 28,750 | 31,250 | - | - | Stock Option (Right to Buy) | |
| EyePoint Pharmaceuticals Inc | Scott David Jones | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.13 per share. | 22 Jan 2024 | 28,750 | 66,712 (0%) | 0% | 10.1 | 291,238 | Common Stock |
| EyePoint Pharmaceuticals Inc | Jones Scott David | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 11.47 per share. | 22 Jan 2024 | 5,416 | 72,128 (0%) | 0% | 11.5 | 62,122 | Common Stock |
| EyePoint Pharmaceuticals Inc | Scott Jones David | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Jan 2024 | 5,416 | 4,584 | - | - | Stock Option (Right to Buy) | |
| EyePoint Pharmaceuticals Inc | Scott David Jones | SVP & Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 22.24 per share. | 22 Jan 2024 | 5,416 | 66,712 (0%) | 0% | 22.2 | 120,437 | Common Stock |
| EyePoint Pharmaceuticals Inc | Scott Jones David | SVP & Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 25.00 per share. | 22 Jan 2024 | 500 | 37,962 (0%) | 0% | 25 | 12,500 | Common Stock |
| EyePoint Pharmaceuticals Inc | Scott David Jones | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.26 per share. | 22 Jan 2024 | 500 | 38,862 (0%) | 0% | 3.3 | 1,630 | Common Stock |
| EyePoint Pharmaceuticals Inc | Scott Jones David | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Jan 2024 | 500 | 91,155 | - | - | Stock Option (Right to Buy) | |
| EyePoint Pharmaceuticals Inc | Scott David Jones | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.90 per share. | 22 Jan 2024 | 400 | 38,362 (0%) | 0% | 12.9 | 5,160 | Common Stock |
| EyePoint Pharmaceuticals Inc | Jones David Scott | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Jan 2024 | 400 | 24,225 | - | - | Stock Option (Right to Buy) | |
| EyePoint Pharmaceuticals Inc | David Jones Scott | SVP & Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 25.00 per share. | 22 Jan 2024 | 400 | 38,462 (0%) | 0% | 25 | 10,000 | Common Stock |
| EyePoint Pharmaceuticals Inc | Jones David Scott | SVP & Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2024 | 42,000 | 42,000 | - | - | Stock Option (Right to Buy) | |
| EyePoint Pharmaceuticals Inc | Jones David Scott | SVP & Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2024 | 21,000 | 21,000 | - | - | Restricted Stock Units | |
| EyePoint Pharmaceuticals Inc | Scott Jones David | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Jan 2024 | 15,285 | 30,570 | - | - | Restricted Stock Units | |
| EyePoint Pharmaceuticals Inc | Jones David Scott | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Jan 2024 | 15,285 | 42,109 (0%) | 0% | 0 | Common Stock | |
| EyePoint Pharmaceuticals Inc | David Jones Scott | SVP & Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 20.40 per share. | 05 Jan 2024 | 4,147 | 37,962 (0%) | 0% | 20.4 | 84,599 | Common Stock |
| EyePoint Pharmaceuticals Inc | David Scott Jones | SVP & Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2023 | 45,855 | 45,855 | - | - | Restricted Stock Units | |
| Shore Bancshares Inc. | David S. Jones | Director | Purchase of securities on an exchange or from another person at price $ 10.99 per share. | 04 May 2023 | 10,000 | 27,192 (0%) | 0% | 11.0 | 109,900 | Common Stock |
| EyePoint Pharmaceuticals Inc | David Scott Jones | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2023 | 5,000 | 28,089 (0%) | 0% | 0 | Common Stock | |
| EyePoint Pharmaceuticals Inc | David Scott Jones | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2023 | 5,000 | 10,000 | - | - | Restricted Stock Units | |
| EyePoint Pharmaceuticals Inc | David Scott Jones | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2023 | 4,967 | 4,967 | - | - | Restricted Stock Units | |
| EyePoint Pharmaceuticals Inc | David Scott Jones | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2023 | 4,967 | 23,089 (0%) | 0% | 0 | Common Stock | |
| EyePoint Pharmaceuticals Inc | David Scott Jones | SVP & Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.17 per share. | 09 Feb 2023 | 1,483 | 26,606 (0%) | 0% | 4.2 | 6,184 | Common Stock |
| EyePoint Pharmaceuticals Inc | David Scott Jones | SVP & Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.17 per share. | 09 Feb 2023 | 1,473 | 25,133 (0%) | 0% | 4.2 | 6,142 | Common Stock |
| Shore Bancshares Inc. | David S. Jones | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2023 | 3,544 | 9,323 (0%) | 0% | 0 | Common Stock | |
| EyePoint Pharmaceuticals Inc | David Scott Jones | SVP & Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2023 | 91,655 | 91,655 | - | - | Stock Option (Right to Buy) | |
| EyePoint Pharmaceuticals Inc | David Scott Jones | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2022 | 4,105 | 16,729 (0%) | 0% | 0 | Common Stock | |
| EyePoint Pharmaceuticals Inc | David Scott Jones | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2022 | 4,105 | 0 | - | - | Restricted Stock Units | |
| EyePoint Pharmaceuticals Inc | David Scott Jones | SVP & Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.95 per share. | 28 Feb 2022 | 1,130 | 15,599 (0%) | 0% | 10.0 | 11,244 | Common Stock |
| EyePoint Pharmaceuticals Inc | David Scott Jones | SVP & Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2022 | 60,000 | 60,000 | - | - | Stock Option (Right to Buy) | |
| EyePoint Pharmaceuticals Inc | David Scott Jones | SVP & Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2022 | 15,000 | 15,000 | - | - | Restricted Stock Units | |
| EyePoint Pharmaceuticals Inc | David Scott Jones | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2022 | 4,966 | 9,934 | - | - | Restricted Stock Units | |
| EyePoint Pharmaceuticals Inc | David Scott Jones | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2022 | 4,966 | 14,097 (0%) | 0% | 0 | Common Stock | |
| EyePoint Pharmaceuticals Inc | David Scott Jones | SVP & Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.13 per share. | 09 Feb 2022 | 1,473 | 12,624 (0%) | 0% | 10.1 | 14,921 | Common Stock |
| Shore Bancshares Inc. | David S. Jones | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2022 | 1,341 | 5,747 (0%) | 0% | 0 | Common Stock | |
| EyePoint Pharmaceuticals Inc | David Scott Jones | SVP & Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Nov 2021 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) | |
| Shore Bancshares Inc. | David S. Jones | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Oct 2021 | 17,192 | 17,192 (0%) | 0% | - | Common Stock | |
| Shore Bancshares Inc. | David S. Jones | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Oct 2021 | 10,730 | 10,730 (0%) | 0% | - | Common Stock | |
| Shore Bancshares Inc. | David S. Jones | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Oct 2021 | 10,315 | 10,315 (0%) | 0% | - | Common Stock | |
| Shore Bancshares Inc. | David S. Jones | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Oct 2021 | 9,279 | 9,279 (0%) | 0% | - | Common Stock | |
| Shore Bancshares Inc. | David S. Jones | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Oct 2021 | 4,406 | 4,406 (0%) | 0% | - | Common Stock | |
| Shore Bancshares Inc. | David S. Jones | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Oct 2021 | 2,538 | 2,538 (0%) | 0% | - | Common Stock | |
| EyePoint Pharmaceuticals Inc | David Scott Jones | SVP & Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2021 | 60,300 | 60,300 | - | - | Stock Option (Right to Buy) | |
| EyePoint Pharmaceuticals Inc | David Scott Jones | SVP & Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2021 | 14,900 | 19,005 | - | - | Restricted Stock Units | |
| EyePoint Pharmaceuticals Inc | David Scott Jones | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2021 | 4,105 | 9,082 (0%) | 0% | 0 | Common Stock | |
| EyePoint Pharmaceuticals Inc | David Scott Jones | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2021 | 4,105 | 4,105 | - | - | Restricted Stock Units | |
| EyePoint Pharmaceuticals Inc | David Scott Jones | SVP & Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.81 per share. | 28 Feb 2021 | 1,702 | 7,380 (0%) | 0% | 10.8 | 18,399 | Common Stock |
| EyePoint Pharmaceuticals Inc | David Scott Jones | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jun 2020 | 41,050 | 82,100 | - | - | Restricted Stock Units | |
| EyePoint Pharmaceuticals Inc | David Scott Jones | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jun 2020 | 41,050 | 41,050 (0%) | 0% | 0 | Common Stock | |
| EyePoint Pharmaceuticals Inc | David Scott Jones | SVP & Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.76 per share. | 30 Jun 2020 | 14,060 | 26,990 (0%) | 0% | 0.8 | 10,643 | Common Stock |